1666 Tong Ren Tang Technologies Co., Ltd.
Tong Ren Tang Technologies Co. (1666) news
Tong Ren Tang Technologies Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1666, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Tong Ren Tang Technologies Co. news
We have not published a story on Tong Ren Tang Technologies Co. yet. When there is news, it will appear here.
Questions about Tong Ren Tang Technologies Co.
What is the ticker symbol of Tong Ren Tang Technologies Co.?
Tong Ren Tang Technologies Co., Ltd. trades under the ticker 1666 on HKEX.
Where is Tong Ren Tang Technologies Co. listed?
Tong Ren Tang Technologies Co., Ltd. is listed on HKEX.
Which country or territory is Tong Ren Tang Technologies Co. listed under?
Our directory records Tong Ren Tang Technologies Co., Ltd. under China.
What does Tong Ren Tang Technologies Co. do?
Our directory classifies Tong Ren Tang Technologies Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Tong Ren Tang Technologies Co.?
The ISIN recorded for Tong Ren Tang Technologies Co., Ltd. is CNE100000585.
Does aibio.space cover Tong Ren Tang Technologies Co.?
aibio.space lists Tong Ren Tang Technologies Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to Tong Ren Tang Technologies Co.?
Companies in our directory listed in the same country and business area as Tong Ren Tang Technologies Co.: Wanbangde Pharmaceutical Holding Group Co., Sunshine Guojian Pharmaceutical (Shanghai) Co., Hunan Er-Kang Pharmaceutical Co., Chongqing Hifuture Information Technology Co., Tianjin Chase Sun Pharmaceutical Co., 3D Medicines.
Investor discussion: Tong Ren Tang Technologies Co.
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Share or debt issue: GENERAL MANDATE TO ISSUE SHARES; PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; PROPOSED AMENDMENTS TO THE RULES OF PROCEDURES OF SHAREHOLDERS' GENERAL MEETINGS; PROPOSED RE-APPOINTMENT OF AUDITOR AND TO AUTHORISE THE BOARD TO FIX ITS REMUNERATION; AND NOTICE OF AGM. Source
Press releases
- HKEXnews
VOLUNTARY ANNOUNCEMENT RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY CHINESE MEDICINE
- HKEXnews
- HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- HKEXnews
- HKEXnews
- HKEXnews
(Updated) FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025
- HKEXnews
- HKEXnews
- HKEXnews
ANNOUNCEMENT ON FINANCIAL INFORMATION FOR THE FIRST QUARTER OF 2026
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
- HKEXnews
- HKEXnews
RENEWAL OF CONTINUING CONNECTED TRANSACTIONS ADVERTISING AGENCY FRAMEWORK AGREEMENT
- HKEXnews
- HKEXnews
Stock chart
Listing details
- Company
- Tong Ren Tang Technologies Co., Ltd.
- Ticker
- 1666
- Listing
- HKEX
- Country or territory
- China
- Business scope
- Pharmaceuticals: Major
- ISIN
- CNE100000585
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio